FDA approves expanded third claim for Bruker in vitro diagnostics system

Aug. 15, 2017
The new claim includes a significant expansion of the microbial reference library for clinical microbiology.

Bruker (Billerica, MA) has received U.S. FDA clearance for its third, further expanded claim for the MALDI Biotyper-CA (MBT-CA) in vitro diagnostics (IVD) system for microbial identification. The new claim includes a significant expansion of the microbial reference library for clinical microbiology by adding 144 new species covering anaerobes, gram-positive and gram-negative bacteria, and yeasts. The library coverage of the MALDI Biotyper-CA now includes 424 microbial species in 333 different groups that are FDA-cleared for the U.S. clinical microbiology market. This further significantly increases the clinical utility of the MBT.

Related: Fast microbe ID system aids multiresistance fight

The third claim now also includes the new disposable MBT Biotargets 96 U.S. IVD, disposable targets based on the company's AnchorChip technology that provides sample concentration. The barcoded 96-spot MBT Biotargets do not waste spots, or require target plate cleaning and the corresponding validation requirements.

The expanded claim 3 library is now available in the U.S. on two different versions of the company's MALDI Biotyper CA system, either based on the standard microflex MALDI-TOF mass spectrometer or on the microflex smart that uses the company's smartbeam laser. Under typical microbial identification conditions, the 200 Hz smartbeam is a lifetime laser for microbial identification, decreases time-to-result, and increases throughput.

The MALDI Biotyper-CA now offers additional workflow tools for U.S. clinical microbiology customers: the MBT Pilot optically guided target preparation assistance tool for reducing specimen transfer human errors, and the MBT Galaxy for automating reagent additions, reducing repetitive motions associated with target preparation, and improving productivity and standardization.

The company's latest third submission showed a 99.8% correlation to sequencing methods, says George Goedesky, Bruker Daltonics Vice President for Microbiology - Americas.

For more information, please visit www.bruker.com.

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)

Sponsored Recommendations

Demonstrating Flexible, Powerful 5-axis Laser Micromachining

Sept. 18, 2024
Five-axis scan heads offer fast and flexible solutions for generating precise holes, contoured slots and other geometries with fully defined cross sections. With a suitable system...

Enhance Your Experiments with Chroma's Spectra Viewer

Sept. 5, 2024
Visualize and compare fluorescence spectra with our interactive Spectra Viewer tool. Easily compare and optimize filters and fluorochromes for your experiments with this intuitive...

Optical Filter Orientation Guide

Sept. 5, 2024
Ensure optimal performance of your optical filters with our Orientation Guide. Learn the correct placement and handling techniques to maximize light transmission and filter efficiency...

Ensure Optimal Performance with Shortpass Filters

Sept. 5, 2024
Achieve precise wavelength blocking with our Shortpass Filters. Ideal for applications requiring effective light transmission and cutoff, these filters ensure optimal performance...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!